TY - JOUR
T1 - Surgical Management of Advanced Pancreatic Neuroendocrine Tumors
T2 - Short-Term and Long-Term Results from an International Multi-institutional Study
AU - Birnbaum, David Jérémie
AU - Turrini, Olivier
AU - Vigano, Luca
AU - Russolillo, Nadia
AU - Autret, Aurélie
AU - Moutardier, Vincent
AU - Capussotti, Lorenzo
AU - Le Treut, Yves Patrice
AU - Delpero, Jean Robert
AU - Hardwigsen, Jean
PY - 2015
Y1 - 2015
N2 - Background: The role of extended resections in the management of advanced pancreatic neuroendocrine tumors (PNETs) is not well defined.Methods: Between 1995 and 2012, 134 patients with PNET underwent isolated (isoPNET group: 91 patients) or extended pancreatic resection (synchronous liver metastases and/or adjacent organs) (advPNET group: 43 patients).Results: The associated resections included 27 hepatectomies, 9 vascular resections, 12 colectomies, 10 gastrectomies, 4 nephrectomies, 4 adrenalectomies, and 3 duodenojejunal resections. R0 was achieved in 41 patients (95 %) in the advPNET. The rates of T3–T4 (73 vs 16 %; p Conclusions: An aggressive surgical approach for locally advanced or metastatic tumors is safe and offers long-term survival.
AB - Background: The role of extended resections in the management of advanced pancreatic neuroendocrine tumors (PNETs) is not well defined.Methods: Between 1995 and 2012, 134 patients with PNET underwent isolated (isoPNET group: 91 patients) or extended pancreatic resection (synchronous liver metastases and/or adjacent organs) (advPNET group: 43 patients).Results: The associated resections included 27 hepatectomies, 9 vascular resections, 12 colectomies, 10 gastrectomies, 4 nephrectomies, 4 adrenalectomies, and 3 duodenojejunal resections. R0 was achieved in 41 patients (95 %) in the advPNET. The rates of T3–T4 (73 vs 16 %; p Conclusions: An aggressive surgical approach for locally advanced or metastatic tumors is safe and offers long-term survival.
UR - http://www.scopus.com/inward/record.url?scp=84924942594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924942594&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-4016-8
DO - 10.1245/s10434-014-4016-8
M3 - Article
C2 - 25190116
AN - SCOPUS:84924942594
VL - 22
SP - 1000
EP - 1007
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 3
ER -